Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib vs Trastuzumab+Pertuzumab in HER2+ Metastatic Breast Cancer
NCT04246502Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04246502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246502.